ABSTRACT
OBJECTIVES: The aim of this study was to evaluate the safety and efficacy of the novel platinum chromium TAXUS Element paclitaxel-eluting stent (PES) compared with the TAXUS Express PES (Boston Scientific, Natick, Massachusetts) in treating coronary artery stenoses. BACKGROUND: The TAXUS Element is a novel thin-strut (81 microm), platinum chromium alloy PES designed to improve radial strength, radiopacity, and deliverability, while safely providing comparable restenosis benefit compared with a previous-generation PES. METHODS: The PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Workhorse (WH) trial is a prospective, randomized (3:1), controlled, multicenter study of the TAXUS Element (vs. TAXUS Express) PES for the treatment of de novo coronary atherosclerotic lesionsSubject(s)
Chromium Alloys/administration & dosage
, Coronary Angiography/standards
, Coronary Stenosis/diagnostic imaging
, Coronary Stenosis/drug therapy
, Drug-Eluting Stents/standards
, Paclitaxel/administration & dosage
, Aged
, Chromium/administration & dosage
, Chromium/adverse effects
, Chromium Alloys/adverse effects
, Drug-Eluting Stents/adverse effects
, Female
, Follow-Up Studies
, Humans
, Male
, Middle Aged
, Paclitaxel/adverse effects
, Platinum/administration & dosage
, Platinum/adverse effects
, Prospective Studies
, Single-Blind Method
, Treatment Outcome